
Torrent Pharmaceuticals Ltd
Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 45,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian bran…
Overview
Torrent Pharma, the Torrent Group's flagship company, is among the country's leading pharmaceutical enterprises. The company was a pioneer in developing the concept of specialty marketing in India and is now listed among the leaders in the therapeutic category of cardiology.
Tech Stack
Funding History
Post Ipo Equity
$40.0M
Apr 2014
ChrysCapital
Post Ipo Secondary
$367.0M
Oct 2024